12:00 AM
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Promacta eltrombopag regulatory update

Ligand said FDA granted Priority Review to an sNDA from GlaxoSmithKline for Promacta eltrombopag to treat thrombocytopenia in adults with chronic HCV infection. GSK submitted the sNDA...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >